Preoperative cholesterol level as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with cyto-reductive nephrectomy

Hakmin Lee, Yong June Kim, Eu Chang Hwang, Seok Ho Kang, Sung-Hoo Hong, Jinsoo Chung, Tae Gyun Kwon, Cheol Kwak, Hyeon Hoe Kim, Jong Jin Oh, Sang Chul Lee, Sung Kyu Hong, Sang Eun Lee, Seok-Soo Byun and KOREAN Renal Cell Carcinoma (KORCC) Group

Abstract

Background: The obesity and lipid metabolism were previously proposed to be related with the clinical outcomes of metastatic renal cell carcinoma (mRCC). We tried to investigate the relationship between preoperative cholesterol level (PCL) and survival outcomes in patients with mRCC.

Methods: We analysed the data of 244 patients initially treated with cyto-reductive nephrectomy after being diagnosed with mRCC. Patients were stratified into two groups according to the PCL cut-off level of 170 mg/dL. The postoperative survival rates were compared using Kaplan-Meier analysis and the possible predictors of patients’ cancer-specific survival (CSS) and overall survival (OS) were tested using multivariate Cox-proportional hazard models.

Results: The low cholesterol group showed significantly worse postoperative CSS ($p = 0.013$) and OS ($p = 0.009$) than the high cholesterol group. On multivariate analysis, low PCL was revealed as an independent predictor of worse CSS (hazard ratio [HR], 2.162; 95% CI, 1.221–3.829; $p = 0.008$) and OS (HR, 2.013; 95% CI, 1.206–3.361; $p = 0.007$). Subsequent subgroup analysis showed that these results were maintained in the clear cell subgroup but not in the non-clear cell subgroup.

Conclusion: Decreased PCL was significantly correlated with worse survival outcomes in patients with mRCC treated with cytoreductive nephrectomy. The underlined mechanism is still uncharted and requires further investigation.

Keywords: Renal cell carcinoma, Cholesterol, Survival, Metastasis, Hypercholesterolemia

Background
Renal cell carcinoma (RCC) is the most frequently diagnosed renal malignancy [1]. Owing to the constant advances of modern imaging technologies, the percentage of incidentally detected renal tumours has constantly increased during the last couple of decades [2, 3]. Although those phenomena brought the overall stage downward migration, a good percentage of patients are still diagnosed with metastatic renal cell carcinoma (mRCC) [3]. The use of cytoreductive nephrectomy in these patients with mRCC was reported to have significant survival benefits in several studies [4]. Therefore, further understanding of prognostic biomarkers is becoming more clinically important in selecting adequate candidates for adjuvant or neoadjuvant therapies for patients with mRCC perioperatively.

Several studies have reported a significant inverse relationship between obesity and RCC prognosis [5–7]. Although obesity is a well-known risk factor for the development of RCC [7], most studies reported that obese...
Patients show more favourable pathology and survival outcomes, a phenomenon known as the “obesity paradox” [5, 6]. A large multicentre study recently analysed a large multi-institutional database of patients with mRCC and showed that patients with a low body mass index (BMI) showed significant worse survival compared to those with a high BMI [6]. They also showed that the high fatty acid synthase (FAS) expression was observed in patients with low BMI was connected to the worse survival outcomes. Their results suggest that the lipid metabolism is one of the important tumour metabolic mechanisms that are essential to tumour survival and progression. Since cholesterol is an essential cellular component that plays a crucial role in lipid metabolism, preoperative serum cholesterol level (PCL) may have significant correlation with prognosis in RCC patients [8]. Unfortunately, only two studies investigated this subject, both of which included small samples of patients with localized RCC but none with mRCC. Therefore, here we aimed to investigate the possible associations of PLC with survival outcomes in patients with mRCC after cytoreductive nephrectomy.

Methods
We retrospectively analysed the data of 281 patients diagnosed with mRCC and initially treated with nephrectomy at multiple centres of South Korea. The informed consent has been waived by an approval of our institutional ethical review boards due to retrospective design (IRB number: B-1702/384–102). After the exclusion of 37 patients (neoadjuvant therapy \[n = 7\], other malignancy \[n = 13\], incomplete information \[n = 17\]), we finally included 244 patients. The clinical and pathological information was retrieved from prospectively managed databases of each institution. Every patient was initially evaluated using chest computed tomography (CT) (or simple radiography), abdominal CT, and bone scan. The PCL was included in the routine chemistry panels which was performed as a part of preoperative anesthetic risk evaluation within 4 weeks preceding the surgery. If there were multiple measurements before the surgical treatment, mean values were regarded as representative.

Pathological stage and histological subtype were determined according to the seventh TNM classification from the American Joint Committee Cancer Guidelines and the Heidelberg recommendations [9, 10]. The nuclear grades of the tumour cells were evaluated according to Fuhrman’s grading system [11]. The survival data and cause of death were determined by a rigorous review of the Korean National Statistical Office’s database and medical records of each hospital. The follow-up protocols varied slightly among institutions or physicians but usually included 3 month intervals after surgery. The receiver operating curve of PCL on the cancer-specific mortality was analysed and the area under the curve was 0.598. Since a PCL of 170 mg/dL showed the maximal Youden index value, the cut-off value was set at 170 mg/dL (Fig. 1). Therefore, the subjects with values ≥170 mg/dL were regarded the high PCL group and the others (PCL < 170 mg/dL) were regarded the low PCL group.

Independent T and chi-square tests were performed to compare the clinicopathological characteristics of the high and low PCL groups. To compare the survival outcomes of the two subgroups, Kaplan–Meier analyses were performed. Using multivariate Cox-proportional hazard models, the possible predictors of overall survival (OS), and cancer-specific survival (CSS) were tested. All of the statistical analyses were performed using SPSS software (version 19.0; SPSS, Chicago, IL, USA). All of the \( p \) values were two-sided and those <0.05 were considered statistically significant.

Results
The clinical and pathological profiles of the entire cohort and subgroups according to the PCL are summarized in Table 1. The median age was 59.0 years (interquartile range [IQR], 52.0–68.0); median tumour diameter was 8.0 cm (IQR, 5.6–10.5), median PCL was 156.0 (IQR, 132.3–173.8), and median follow-up time was 13.0 months (IQR, 6.0–26.5). There were 88 patients in the high PCL group and 156 patients in the low PCL group. The low PCL group showed significantly lower haemoglobin level \((p < 0.001)\) and higher platelet level \((p = 0.038)\) than the high PCL group, but no significant differences were noted in the other clinical characteristics or pathological outcomes between the two groups.

After a median follow-up of 12.0 months (IQR, 7.0–23.0), 85 patients died because of RCC. A total of 101 all-cause mortalities occurred after a median follow-up of 13.0 months (IQR, 7.0–23.5). The low PCL group showed significantly worse CSS \((p = 0.013)\) and OS \((p = 0.009)\) than the high
The results from univariate Cox proportional analyses on CSS and OS were summarized in Table 2. Multivariate Cox proportional analysis revealed that low PCL was the independent predictor for worse CSS (HR, 2.162; 95% CI, 1.221–3.829; \( p = 0.008 \)) and OS (HR, 2.013; 95% CI, 1.206–3.361; \( p = 0.007 \)) (Table 3). When we stratified the patients by tumour histology (clear cell versus non-clear cell types), low PCL was revealed as an independent predictor for worse CSS (HR, 2.312; 95% CI, 1.274–4.193; \( p = 0.006 \)) and OS (HR, 2.204; 95% CI, 1.279–3.799; \( p = 0.007 \))

### Table 1 Summarization of clinico-pathologic factors of entire patients and according to the subgroups stratified by the cholesterol level of 170 mg/dL cut-off

|                      | Entire patients (\( n = 244 \)) | High PCL group (\( n = 72 \)) | Low PCL group (\( n = 172 \)) | \( p \) value |
|----------------------|----------------------------------|--------------------------------|-------------------------------|---------------|
| **Median (IQR) or Number (percent)** |                                  |                                |                               |               |
| **Age (y)**          | 59.0 (52.0–68.0)                  | 57.5 (52.0–67.0)                | 60.0 (51.3–68.8)              | 0.981         |
| **BMI (kg/m\(^2\))** | 23.0 (21.0–24.8)                  | 23.5 (21.8–42.8)                | 22.9 (20.8–24.9)              | 0.239         |
| **Sex (male)**       | 185 (75.8%)                       | 50 (69.4%)                      | 135 (78.5%)                   | 0.001         |
| **Serum Albumin (g/dL)** | 4.0 (3.5–4.3)                      | 4.3 (3.9–4.4)                   | 3.9 (3.4–4.2)                 | < 0.001       |
| **Hemoglobin (g/dL)** | 12.1 (10.6–13.6)                  | 13.1 (11.7–14.7)                | 11.8 (10.3–13.1)              | < 0.001       |
| **Platelet (k/dL)**  | 274.5 (132.3–173.8)               | 271.5 (212.5–320.5)             | 299.8 (222.0–378.8)           | 0.038         |
| **PLC (mg/dL)**      | 156.0 (132.3–173.8)               | 190 (178–205.8)                 | 139.1 (126.3–157.8)           |               |
| **Corrected calcium (mg/dL)** | 9.2 (8.9–9.7)                      | 9.4 (9.0–9.8)                   | 9.5 (8.8–9.6)                 |               |
| **ECOG score (≥2)**  | 79 (32.4%)                        | 22 (30.6%)                      | 57 (33.1%)                    | 0.765         |
| **Diabetes mellitus**| 60 (24.7%)                        | 14 (19.7%)                      | 46 (26.7%)                    | 0.326         |
| **Hypertension**     | 120 (49.6%)                       | 33 (46.5%)                      | 87 (50.9%)                    | 0.574         |
| **Tumor size (cm)**  | 8.0 (5.6–10.5)                    | 6.5 (5.0–9.5)                   | 8.7 (6.1–11.0)                | 0.407         |
| **Clinical stage (23)** | 138 (56.6%)                      | 32 (44.4%)                      | 106 (61.6%)                   | 0.059         |
| **Metastatic sites** |                                  |                                |                               | 0.541         |
| **Lung**             | 78 (32.0%)                        | 23 (31.9%)                      | 55 (32.0%)                    |               |
| **Liver**            | 7 (2.7%)                          | 1 (1.4%)                        | 5 (2.9%)                      |               |
| **Bone**             | 24 (9.9%)                         | 10 (13.9%)                      | 14 (8.1%)                     |               |
| **Non-regional LNI** | 2 (1.0%)                          | 0 (0%)                          | 2 (1.2%)                      |               |
| **Adrenal gland**    | 8 (3.3%)                          | 4 (5.6%)                        | 4 (2.3%)                      |               |
| **Multiple metastasis** | 10 (4.1%)                        | 3 (4.2%)                        | 7 (4.1%)                      |               |
| **Information missing** | 108 (44.3%)                     | 33 (45.8%)                      | 75 (43.6%)                    |               |
| **Miscellaneous**    | 2 (1.0%)                          | 0 (0%)                          | 2 (1.2%)                      |               |
| **Pathologic stage** |                                  |                                |                               | 0.060         |
| **pT1**              | 60 (24.6%)                        | 24 (33.3%)                      | 36 (20.9%)                    |               |
| **pT2**              | 36 (14.8%)                        | 11 (15.3%)                      | 25 (14.5%)                    |               |
| **pT3**              | 117 (48.0%)                       | 33 (45.8%)                      | 84 (48.8%)                    |               |
| **pT4**              | 31 (12.7%)                        | 4 (5.6%)                        | 27 (15.7%)                    |               |
| **Fuhrman grade**    |                                  |                                |                               | 0.424         |
| \( ≤ 2 \)           | 34 (13.9%)                        | 12 (16.7%)                      | 22 (12.8%)                    |               |
| \( ≥ 3 \)           | 210 (86.1%)                       | 60 (83.3%)                      | 150 (87.2%)                   |               |
| **Histologic subtype** |                                |                                |                               | 0.214         |
| **Clear cell**       | 213 (87.3%)                       | 67 (93.1%)                      | 146 (84.9%)                   |               |
| **Papillary**        | 13 (5.3%)                         | 2 (2.8%)                        | 11 (6.4%)                     |               |
| **Chromophobe**      | 4 (1.6%)                          | 0 (0%)                          | 4 (2.3%)                      |               |
| **Collecting duct**  | 5 (2.0%)                          | 1 (1.4%)                        | 4 (2.3%)                      |               |
| **Unclassified**     | 9 (3.7%)                          | 2 (2.8%)                        | 7 (4.1%)                      |               |

IQR interquartile range, PCL preoperative cholesterol level, BMI body mass index, ECOG Eastern Cooperative Oncology Group, LNI lymph node invasion
there were no significant relationships between PCL and survival outcomes in the non-clear cell subgroup (all p values >0.05). Subsequently, we further stratified the entire patient cohort into three risk groups (favourable, intermediate, poor) according to Heng's model. We observed worse survival outcomes in the low PCL group, but the results did not reach statistical significance due to the small number of subjects (Table 4).

Discussion
In the present study, we found that low PCL was independently correlated with worse survival outcomes in mRCC patients treated by cytoreductive nephrectomy. Interestingly, PCL showed significant results in the clear cell type RCC but not in the non-clear cell RCC, which implies that lipid metabolism is mainly associated with clear cell subtype RCC. The PCL showed high HR in all three risk groups according to Heng's criteria, although the results were non-significant due to the small number of included subjects.

Malignant cells have the notable feature of invasiveness and relentless proliferation, both of which require profound energy and raw materials. To support those abilities, most cancer cells have special metabolisms that enable them to promote their survival. This phenomenon has been termed “metabolic transformation” [12]. Among those, the most well-known metabolism in cancer cells is the “Warburg effect” [13]. Warburg et al. found that cancer cells produced adenosine triphosphate by non-aerobic glycolysis even in circumstances of sufficient oxygen, and this peculiar metabolism is beneficial because it produces less reactive oxygen species, which are hazardous to cancer cells due to the oxidative stress. Along with glucose metabolism, lipid metabolism is crucial to maintaining cancer proliferation and finishing the new building blocks because proliferating cells require plenty of nucleotides, fatty acids, membrane lipids, and proteins. Many cancer cells show high rates of de novo lipid synthesis [14]. Since cholesterol is an essential component of cellular membranes and important in energy production of tumour

Table 2 Univariate Cox regression model adjusted for possible predictors estimating cancer-specific and overall survival in 244 patients treated with cyto-reductive nephrectomy for metastatic renal cell carcinoma

| predictor             | Cancer-specific survival | Overall survival |
|-----------------------|--------------------------|------------------|
|                       | HR 95% CI of HR p value  | HR 95% CI of HR  p value |
| Age                   |                          |                  |
| BMI (kg/m²)Reference  | 1.004 0.986–1.023 0.679  | 1.005 0.989–1.023 0.530 |
| 20–25                 | 0.373 0.182–0.762 0.007  | 0.387 0.202–0.743 0.004 |
| ≥ 25                  | 0.373 0.182–0.762 0.007  | 0.387 0.202–0.743 0.004 |
| Albumin (g/dL)Reference  | 0.515 0.290–0.916 0.024  | 0.485 0.286–0.822 0.007 |
| 3.5–4.3               | 0.515 0.290–0.916 0.024  | 0.485 0.286–0.822 0.007 |
| Heng's criteria       | Reference (Low risk)     | Reference (Low risk) |
| Intermediate risk     | 1.265 0.729–2.198 0.403  | 1.188 0.720–1.961 0.499 |
| High risk             | 1.842 0.957–3.546 0.067  | 1.806 0.999–3.266 0.050 |
| Cholesterol level cat.| 2.251 1.285–3.941 0.005  | 2.100 1.272–3.466 0.004 |

HR hazard ratio, CI confidence interval, BMI body mass index, cat. Categorical variable
survival, the several previous studies investigated the relationship between cholesterol level and cancer development [15–17]. A large epidemiologic study analysed 33,368 Japanese subjects and concluded the presence of an increased incidence of stomach and liver cancers in patients having low cholesterol levels [15]. Another prospective study by Asano et al. also demonstrated that there were inverse association between cholesterol level and gastric cancer incidence after analysing the data of 2604 subjects for 14 years follow-up [16]. Kitahara et al. recently performed a retrospective analysis of a large database from South Korea with 1 million subjects and concluded that cholesterol level was

| Table 3 | Multivariate Cox regression model adjusted for possible predictors estimating cancer-specific and overall survival in 244 patients treated with cyto-reductive nephrectomy for metastatic renal cell carcinoma |
|---------|----------------------------------------------------------------------------------------------------------|
|         | Cancer-specific survival                                                                                     | Overall survival                                                                                     |
|         | HR  | 95% CI of HR | p value | HR  | 95% CI of HR | p value |
| Age     | 1.002 | 0.983–1.021 | 0.865 | 1.003 | 0.986–1.021 | 0.713 |
| BMI (kg/m²) | Reference (< 20)                                | Reference (< 20)                                | Reference (< 20)                                |
|         | 0.792 | 0.459–1.369 | 0.404 | 0.805 | 0.485–1.336 | 0.402 |
| ≥ 25    | 0.443 | 0.202–0.924 | 0.030 | 0.466 | 0.232–0.936 | 0.032 |
| Albumin (g/dL) | Reference (< 3.5)                          | Reference (< 3.5)                          | Reference (< 3.5)                          |
|         | 0.776 | 0.440–1.370 | 0.382 | 0.716 | 0.426–1.204 | 0.208 |
| ≥ 4.3   | 0.784 | 0.399–1.544 | 0.482 | 0.713 | 0.383–1.328 | 0.287 |
| Heng’s criteria | Reference (Low risk)                      | Reference (Low risk)                      | Reference (Low risk)                      |
| Intermediate risk | 1.095 | 0.623–1.926 | 0.752 | 1.033 | 0.619–1.725 | 0.902 |
| High risk | 1.185 | 0.550–2.553 | 0.664 | 1.132 | 0.565–2.270 | 0.727 |
| Cholesterol level (cat.) | 2.162 | 1.221–3.829 | 0.008 | 2.013 | 1.206–3.361 | 0.007 |
| Age     | 1.002 | 0.983–1.021 | 0.830 | 1.003 | 0.986–1.021 | 0.701 |
| BMI (kg/m²) | Reference (< 20)                                | Reference (< 20)                                | Reference (< 20)                                |
|         | 0.827 | 0.479–1.430 | 0.497 | 0.857 | 0.517–1.420 | 0.549 |
| ≥ 25    | 0.462 | 0.214–0.997 | 0.049 | 0.503 | 0.249–1.017 | 0.056 |
| Albumin (g/dL) | Reference (< 3.5)                          | Reference (< 3.5)                          | Reference (< 3.5)                          |
|         | 0.882 | 0.498–1.561 | 0.665 | 0.789 | 0.468–1.327 | 0.371 |
| ≥ 4.3   | 0.892 | 0.437–1.821 | 0.753 | 0.769 | 0.401–1.473 | 0.428 |
| Heng’s criteria | Reference (Low risk)                      | Reference (Low risk)                      | Reference (Low risk)                      |
| Intermediate | 1.060 | 0.601–1.870 | 0.840 | 1.024 | 0.613–1.712 | 0.927 |
| High risk | 1.235 | 0.576–2.649 | 0.588 | 1.193 | 0.596–2.389 | 0.618 |
| Cholesterol level (cont.) | 0.993 | 0.987–0.999 | 0.032 | 0.995 | 0.989–1.000 | 0.063 |

HR hazard ratio, CI confidence interval, BMI body mass index, cont. Continuous variable, cat. Categorical variable

| Table 4 | Multivariate Cox hazard ratio models for the impact of low cholesterol on cancer-specific and overall survival after surgical treatment of metastatic renal cell carcinoma |
|---------|----------------------------------------------------------------------------------------------------------|
|         | Cancer-specific survival                                                                                     | Overall survival                                                                                     |
|         | HR  | 95% CI of HR | p-value | HR  | 95% CI of HR | p-value |
| Entire cohorts | 2.162 | 1.221–3.829 | 0.008 | 2.013 | 1.206–3.361 | 0.007 |
| Subgroups according to the tumor histology | | |
| Clear cell histology | 2.312 | 1.274–4.193 | 0.006 | 2.204 | 1.279–3.799 | 0.004 |
| Other histology | 0.767 | 0.076–7.771 | 0.822 | 0.285 | 0.043–1.879 | 0.192 |
| Subgroups according to the Heng’s model | | |
| Favorable risk | 1.556 | 0.487–4.967 | 0.455 | 1.767 | 0.602–5.185 | 0.300 |
| Intermediate | 1.809 | 0.907–3.611 | 0.093 | 1.583 | 0.851–2.947 | 0.147 |
| Poor | 1.538 | 0.339–6.972 | 0.577 | 1.735 | 0.406–7.416 | 0.457 |

Multivariate analyses were adjusted for age, body mass index, Heng’s risk group, preoperative albumin and cholesterol level. HR hazard ratio, CI confidence interval
correlated with increased incidence of several malignancies [17]. However, the influence of cholesterol was quite heterogeneous between the different malignancies. From their results, prostate, colon, and breast cancer showed high incidences in patients with high cholesterol, whereas liver, stomach, and lung cancer showed high incidences in patients with low cholesterol, showing that the relationship is quite variable and cancer-specific. Apart from the increased incidences, little has been investigated about the relationship between cholesterol level and cancer prognosis. Ohno et al. analysed 364 clear cell RCC patients and reported that a high PCL was associated with better CSS, although the findings of their multivariate analysis were not statistically significant due to a small number of subjects [18]. Another study by Martino et al. analysed a larger cohort of 867 subjects with localized RCC and concluded that low PCL independently correlated with worse CSS [19]. To our best knowledge, our study is the first to evaluate the prognostic value of PCL in patients with mRCC.

As the terminology “clear cell” indicates, the clear cell type of RCC accumulates significant amounts of cholesterol ester and glycogen in the cytosol [20]. Furthermore, several genes involved in lipid metabolism were previously reported to be related with clear cell type RCC progression [21]. In the present study, PCL showed significant associations in clear cell subtypes but not in non-clear cell subtypes, which implicates these relationships are intact only in the clear cell subtype. However, the exact mechanism or pathways underneath these phenomena are obscure and require elucidation.

Our study has several important limitations. First, the retrospective design and information gathering method are not immune to recall bias. Second, we could not analyse the influence of specific drugs such as statins. Third, patients received different salvage or palliative therapies from different attending physicians. Finally, we included only mRCC patients treated with nephrectomy, and further studies are needed to confirm our findings in all patients with mRCC.

Conclusion
Preoperative serum cholesterol level was associated with worse survival outcomes in patients with mRCC after treatment with cytoreductive nephrectomy. Further basic studies are needed to elucidate the exact lipid metabolism underlying this peculiar phenomenon.

Abbreviations
BMI: Body mass index; CSS: Cancer-specific survival; CT: Computed tomography; FAS: Fatty acid synthase; HR: Hazard ratio; IQR: Interquartile range; mRCC: Metastatic renal cell carcinoma; OS: Overall survival; PCL: Preoperative serum cholesterol level; RCC: Renal cell carcinoma

Acknowledgments
KOrean Renal Cell Carcinoma (KORCC) Group.
References

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277.
2. Jayson A, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998;51:203–5.
3. Hollingsworth JM, Miller DC, Daignault S, et al. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98:1331–4.
4. Hong X, Li F, Tang K, et al. Prognostic value of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: a meta-analysis. Int Urol Nephrol. 2016;48(6):967–76.
5. Choi Y, Park B, Jeong BC, et al. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. Int J Cancer. 2013;132(3):625–34.
6. Albiges L, Hakimi AA, Xie W et al. Body mass index and metastatic renal cell carcinoma: clinical and biological correlations. J Clin Oncol 2016; pii: JCO667311. [Epub ahead of print].
7. Hakimi AA, Furberg H, Zabor EC, et al. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J Natl Cancer Inst. 2013;105(24):1862–70.
8. Ye J, DeBose-Boyd RA. Regulation of cholesterol and fatty acid synthesis. Cold Spring Harb Perspect Biol 2011; 3(7).
9. Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2011;17:1471–4.
10. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183:131–3.
11. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655–63.
12. Cairns RA, Harris I, McCracken S, Mak TW. Cancer cell metabolism. Cold Spring Harb Symp Quant Biol. 2011;76:299–311.
13. Warburg O. On respiratory impairment in cancer cells. Science. 1956;124:269–70.
14. Medes G, Thomas A. Weinhouse S metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res. 1953;13:27–9.
15. Iso H, Ikeda A, Inoue M, Sato S, Tsugane S, JPHC Study Group. Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int J Cancer. 2009;125(11):2679–86.
16. Asano K, Kubo M, Yonemoto K, et al. Impact of serum total cholesterol on the incidence of gastric cancer in a population-based prospective study: the Hisayama study. Int J Cancer. 2008;122(4):909–14.
17. Kitaheara CM, Berrington de González A et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011;29(12):1592–8.
18. Kitaheara CM, Berrington de González A, Freedman ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011;29:1592–8.
19. Ohno Y, Nakashima J, Nakagami Y, et al. Clinical implications of preoperative serum total cholesterol in patients with clear cell renal cell carcinoma. Urology. 2014;83:154–8.
20. de Martino M, Leitner CV, Seemann C, et al. Preoperative serum cholesterol is an independent prognostic factor for patients with renal cell carcinoma (RCC). BJU Int. 2015;115:397–404.
21. Yao M, Tabuchi H, Nagashima Y, et al. Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J Pathol. 2005;205(3):377–87.